Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 24
Filter
1.
Zhen Ci Yan Jiu ; 49(4): 331-340, 2024 Apr 25.
Article in English, Chinese | MEDLINE | ID: mdl-38649200

ABSTRACT

OBJECTIVES: To observe whether acupuncture up-regulates chemokine CXC ligand 1 (CXCL1) in the brain to play an analgesic role through CXCL1/chemokine CXC receptor 2 (CXCR2) signaling in adjuvant induced arthritis (AIA) rats, so as to reveal its neuro-immunological mechanism underlying improvement of AIA. METHODS: BALB/c mice with relatively stable thermal pain reaction were subjected to planta injection of complete Freund adjuvant (CFA) for establishing AIA model, followed by dividing the AIA mice into simple AF750 (fluorochrome) and AF750+CXCL1 groups (n=2 in each group). AF750 labeled CXCL1 recombinant protein was then injected into the mouse's tail vein to induce elevation of CXCL1 level in blood for simulating the effect of acupuncture stimulation which has been demonstrated by our past study. In vivo small animal imaging technology was used to observe the AF750 and AF750+CXCL1-labelled target regions. After thermal pain screening, the Wistar rats with stable pain reaction were subjected to AIA modeling by injecting CFA into the rat's right planta, then were randomized into model and manual acupuncture groups (n=12 in each group). Other 12 rats that received planta injection of saline were used as the control group. Manual acupuncture (uniform reinforcing and reducing manipulations) was applied to bilateral "Zusanli" (ST36) for 4×2 min, with an interval of 5 min between every 2 min, once daily for 7 days. The thermal pain threshold was assessed by detecting the paw withdrawal latency (PWL) using a thermal pain detector. The contents of CXCL1 in the primary somatosensory cortex (S1), medial prefrontal cortex, nucleus accumbens, amygdala, periaqueductal gray and rostroventromedial medulla regions were assayed by using ELISA, and the expression levels of CXCL1, CXCR2 and mu-opioid receptor (MOR) mRNA in the S1 region were detected using real time-quantitative polymerase chain reaction. The immune-fluorescence positive cellular rate of CXCL1 and CXCR2 in S1 region was observed after immunofluorescence stain. The immunofluorescence double-stain of CXCR2 and astrocyte marker glial fibrillary acidic protein (GFAP) or neuron marker NeuN or MOR was used to determine whether there is a co-expression between them. RESULTS: In AIA mice, results of in vivo experiments showed no obvious enrichment signal of AF750 or AF750+CXCL1 in any organ of the body, while in vitro experiments showed that there was a stronger fluorescence signal of CXCL1 recombinant protein in the brain. In rats, compared with the control group, the PWL from day 0 to day 7 was significantly decreased (P<0.01) and the expression of CXCR2 mRNA in the S1 region significantly increased in the model group (P<0.05), while in comparison with the model group, the PWL from day 2 to day 7, CXCL1 content, CXCR2 mRNA expression and CXCR2 content, and MOR mRNA expression in the S1 region were significantly increased in the manual acupuncture group (P<0.05, P<0.01). Immunofluorescence stain showed that CXCR2 co-stained with NeuN and MOR in the S1 region, indicating that CXCR2 exists in neurons and MOR-positive neurons but not in GFAP positive astrocytes. CONCLUSIONS: Acupuncture can increase the content of CXCL1 in S1 region, up-regulate CXCR2 on neurons in the S1 region and improve MOR expression in S1 region of AIA rats, which may contribute to its effect in alleviating inflammatory pain.


Subject(s)
Acupuncture Therapy , Arthritis, Experimental , Chemokine CXCL1 , Receptors, Interleukin-8B , Somatosensory Cortex , Animals , Humans , Male , Mice , Rats , Acupuncture Points , Arthritis, Experimental/therapy , Arthritis, Experimental/metabolism , Arthritis, Experimental/genetics , Chemokine CXCL1/metabolism , Chemokine CXCL1/genetics , Inflammation/therapy , Inflammation/metabolism , Inflammation/genetics , Mice, Inbred BALB C , Pain/metabolism , Pain/genetics , Pain Management , Rats, Wistar , Receptors, Interleukin-8B/metabolism , Receptors, Interleukin-8B/genetics , Signal Transduction , Somatosensory Cortex/metabolism
2.
Cell Commun Signal ; 19(1): 89, 2021 08 30.
Article in English | MEDLINE | ID: mdl-34461944

ABSTRACT

BACKGROUND: Metastasis represents the leading cause of death in patients with breast cancer. Traditional Chinese medicine is particularly appreciated for metastatic diseases in Asian countries due to its benefits for survival period prolongation and immune balance modulation. However, the underlying molecular mechanisms remain largely unknown. This study aimed to explore the antimetastatic effect and immunomodulatory function of a clinical formula Aiduqing (ADQ). METHODS: Naive CD4+ T cells, regulatory T cells (Tregs), and CD8+ T cells were sorted by flow cytometry. Then, breast cancer cells and these immune cells were co-cultured in vitro or co-injected into mice in vivo to simulate their coexistence. Flow cytometry, ELISA, qPCR, double luciferase reporter gene assay, and chromatin immunoprecipitation assay were conducted to investigate the immunomodulatory and antimetastatic mechanisms of ADQ. RESULTS: ADQ treatment by oral gavage significantly suppressed 4T1-Luc xenograft growth and lung metastasis in the orthotopic breast cancer mouse model, without noticeable hepatotoxicity, nephrotoxicity, or hematotoxicity. Meanwhile, ADQ remodeled the immunosuppressive tumor microenvironment (TME) by increasing the infiltration of tumor-infiltrating lymphocytes (TILs) and cytotoxic CD8+ T cells, and decreasing the infiltration of Tregs, naive CD4+ T cells, and tumor-associated macrophages (TAMs). Molecular mechanism studies revealed that ADQ remarkably inhibited CXCL1 expression and secretion from TAMs and thus suppressed the chemotaxis and differentiation of naive CD4+ T cells into Tregs, leading to the enhanced cytotoxic effects of CD8+ T cells. Mechanistically, TAM-derived CXCL1 promoted the differentiation of naive CD4+ T cells into Tregs by transcriptionally activating the NF-κB/FOXP3 signaling. Lastly, mouse 4T1-Luc xenograft experiments validated that ADQ formula inhibited breast cancer immune escape and lung metastasis by suppressing the TAM/CXCL1/Treg pathway. CONCLUSIONS: This study not only provides preclinical evidence supporting the application of ADQ in inhibiting breast cancer metastasis but also sheds novel insights into TAM/CXCL1/NF-κB/FOXP3 signaling as a promising therapeutic target for Treg modulation and breast cancer immunotherapy. Video Abstract.


Subject(s)
Antineoplastic Agents/pharmacology , Breast Neoplasms/drug therapy , Chemokine CXCL1/genetics , Medicine, Chinese Traditional , Animals , Antineoplastic Agents/chemistry , Breast Neoplasms/genetics , Breast Neoplasms/pathology , CD4-Positive T-Lymphocytes/drug effects , CD8-Positive T-Lymphocytes/drug effects , Cell Differentiation/drug effects , Cell Line, Tumor , Cell Movement/drug effects , Cell Proliferation/drug effects , Humans , Mice , Neoplasm Metastasis , T-Lymphocytes, Regulatory/drug effects , Tumor Microenvironment/drug effects , Tumor-Associated Macrophages/drug effects , Xenograft Model Antitumor Assays
3.
Tumour Biol ; 43(1): 37-55, 2021.
Article in English | MEDLINE | ID: mdl-33935122

ABSTRACT

BACKGROUND: Green synthesized nanoparticles have been earmarked for use in nanomedicine including for the development of better anticancer drugs. OBJECTIVE: The aim of this study was to undertake biochemical evaluation of anticancer activities of green synthesized silver nanoparticles (AgNPs) from ethanolic extracts of fruits (AgNPs-F) and leaves (AgNPs-L) of Annona muricata. METHODS: Previously synthesized silver nanoparticles were used for the study. The effects of the AgNPs and 5-Fluorouracil were studied on PC3, HeLa and PNT1A cells. The resazurin, migration and colonogenic assays as well as qRT-PCR were employed. RESULTS: The AgNPs-F displayed significant antiproliferative effects against HeLa cells with an IC50 of 38.58µg/ml and PC3 cells with an IC50 of 48.17µg/ml but selectively spared normal PNT1A cells (selectivity index of 7.8), in comparison with first line drug 5FU and AgNPs-L whose selectivity index were 3.56 and 2.26 respectively. The migration assay revealed potential inhibition of the metastatic activity of the cells by the AgNPs-F while the colonogenic assay indicated the permanent effect of the AgNPs-F on the cancer cells yet being reversible on the normal cells in contrast with 5FU and AgNPs-L. CASP9 was significantly over expressed in all HeLa cells treated with the AgNPs-F (1.53-fold), AgNPs-L (1.52-fold) and 5FU (4.30-fold). CXCL1 was under expressed in HeLa cells treated with AgNPs-F (0.69-fold) and AgNPs-L (0.58-fold) and over expressed in cells treated with 5FU (4.95-fold), but the difference was not statistically significant. CXCR2 was significantly over expressed in HeLa cells treated with 5FU (8.66-fold) and AgNPs-F (1.12-fold) but under expressed in cells treated with AgNPs-L (0.76-fold). CONCLUSIONS: Here we show that biosynthesized AgNPs especially AgNPs-F can be used in the development of novel and better anticancer drugs. The mechanism of action of the AgNPs involves activation of the intrinsic apoptosis pathway through upregulation of CASP9 and concerted down regulation of the CXCL1/ CXCR2 gene axis.


Subject(s)
Annona/chemistry , Antineoplastic Agents/pharmacology , Caspase 9/genetics , Chemokine CXCL1/genetics , Metal Nanoparticles , Receptors, Interleukin-8B/genetics , Silver/pharmacology , Adenocarcinoma/pathology , Cell Line , Cell Movement/drug effects , Cell Proliferation/drug effects , Cell Survival/drug effects , Female , Gene Expression Regulation, Neoplastic/drug effects , Green Chemistry Technology , Humans , Male , Plant Extracts/chemistry , Plant Extracts/pharmacology , Prostatic Neoplasms/pathology , Uterine Cervical Neoplasms/pathology
4.
Front Endocrinol (Lausanne) ; 12: 601160, 2021.
Article in English | MEDLINE | ID: mdl-33815271

ABSTRACT

Background: Non-alcoholic fatty liver disease (NAFLD) is a complex multifactorial disorder that is characterised by dysfunctional lipid metabolism and cholesterol homeostasis, and a related chronic inflammatory response. NAFLD has become the most common cause of chronic liver disease in many countries, and its prevalence continues to rise in parallel with increasing rates of obesity. Here, we evaluated the putative NAFLD-attenuating effects of a multicomponent medicine consisting of 24 natural ingredients: Hepar compositum (HC-24). Methods: Ldlr-/-.Leiden mice were fed a high-fat diet (HFD) with a macronutrient composition and cholesterol content comparable to human diets for 24 weeks to induce obesity-associated metabolic dysfunction, including hepatic steatosis and inflammation. HC-24 or vehicle control was administered intraperitoneally 3 times/week (1.5 ml/kg) for the last 18 weeks of the study. Histological analyses of liver and adipose tissue were combined with extensive hepatic transcriptomics analysis. Transcriptomics results were further substantiated with ELISA, immunohistochemical and liver lipid analyses. Results: HFD feeding induced obesity and metabolic dysfunction including adipose tissue inflammation and increased gut permeability. In the liver, HFD-feeding resulted in a disturbance of cholesterol homeostasis and an associated inflammatory response. HC-24 did not affect body weight, metabolic risk factors, adipose tissue inflammation or gut permeability. While HC-24 did not alter total liver steatosis, there was a pronounced reduction in lobular inflammation in HC-24-treated animals, which was associated with modulation of genes and proteins involved in inflammation (e.g., neutrophil chemokine Cxcl1) and cholesterol homeostasis (i.e., predicted effect on 'cholesterol' as an upstream regulator, based on gene expression changes associated with cholesterol handling). These effects were confirmed by CXCL1 ELISA, immunohistochemical staining of neutrophils and biochemical analysis of hepatic free cholesterol content. Intrahepatic free cholesterol levels were found to correlate significantly with the number of inflammatory aggregates in the liver, thereby providing a potential rationale for the observed anti-inflammatory effects of HC-24. Conclusions: Free cholesterol accumulates in the liver of Ldlr-/-.Leiden mice under physiologically translational dietary conditions, and this is associated with the development of hepatic inflammation. The multicomponent medicine HC-24 reduces accumulation of free cholesterol and has molecular and cellular anti-inflammatory effects in the liver.


Subject(s)
Cholesterol/metabolism , Non-alcoholic Fatty Liver Disease/drug therapy , Plant Extracts/administration & dosage , Animals , Chemokine CXCL1/genetics , Chemokine CXCL1/metabolism , Diet, High-Fat/adverse effects , Humans , Lipid Metabolism/drug effects , Liver/drug effects , Liver/immunology , Liver/metabolism , Male , Mice , Mice, Knockout , Non-alcoholic Fatty Liver Disease/genetics , Non-alcoholic Fatty Liver Disease/immunology , Non-alcoholic Fatty Liver Disease/metabolism , Receptors, LDL/genetics , Receptors, LDL/immunology
5.
FASEB J ; 35(4): e21354, 2021 04.
Article in English | MEDLINE | ID: mdl-33749892

ABSTRACT

ω3 fatty acids show potent bioactivities via conversion into lipid mediators; therefore, metabolism of dietary lipids is a critical determinant in the properties of ω3 fatty acids in the control of allergic inflammatory diseases. However, metabolic progression of ω3 fatty acids in the skin and their roles in the regulation of skin inflammation remains to be clarified. In this study, we found that 12-hydroxyeicosapentaenoic acid (12-HEPE), which is a 12-lipoxygenase metabolite of eicosapentaenoic acid, was the prominent metabolite accumulated in the skin of mice fed ω3 fatty acid-rich linseed oil. Consistently, the gene expression levels of Alox12 and Alox12b, which encode proteins involved in the generation of 12-HEPE, were much higher in the skin than in the other tissues (eg, gut). We also found that the topical application of 12-HEPE inhibited the inflammation associated with contact hypersensitivity by inhibiting neutrophil infiltration into the skin. In human keratinocytes in vitro, 12-HEPE inhibited the expression of two genes encoding neutrophil chemoattractants, CXCL1 and CXCL2, via retinoid X receptor α. Together, the present results demonstrate that the metabolic progression of dietary ω3 fatty acids differs in different organs, and identify 12-HEPE as the dominant ω3 fatty acid metabolite in the skin.


Subject(s)
Chemokine CXCL1/metabolism , Dermatitis, Contact/prevention & control , Eicosapentaenoic Acid/analogs & derivatives , Keratinocytes/drug effects , Animals , Antibodies, Monoclonal/drug effects , Antibodies, Monoclonal/metabolism , Bone Marrow Cells , Chemokine CXCL1/genetics , Diet , Dinitrofluorobenzene , Down-Regulation , Eicosapentaenoic Acid/pharmacology , Female , Gene Expression Regulation/drug effects , HaCaT Cells , Humans , Linseed Oil/administration & dosage , Linseed Oil/metabolism , Mice
6.
Phytomedicine ; 78: 153331, 2020 Nov.
Article in English | MEDLINE | ID: mdl-32911383

ABSTRACT

BACKGROUND: Breast cancer is the most common malignancy in women and metastasis is the leading cause of breast cancer-related deaths. Our previous studies have shown that XIAOPI formula, a newly approved drug by the State Food and Drug Administration of China (SFDA), can dramatically inhibit breast cancer metastasis by modulating the tumor-associated macrophages/C-X-C motif chemokine ligand 1 (TAMs/CXCL1) pathway. However, the bioactive compound accounting for the anti-metastatic effect of XIAOPI formula remains unclear. PURPOSE: This study was designed to separate the anti-metastatic bioactive compound from XIAOPI formula and to elucidate its action mechanisms. STUDY DESIGN/METHODS: TAMs/CXCL1 promoter activity-guided fractionation and multiple chemical structure identification approaches were conducted to screen the bioactive compound from XIAOPI formula. Breast cancer cells and TAMs were co-cultured in vitro or co-injected in vivo to simulate their coexistence. Multiple molecular biology experiments, zebrafish breast cancer xenotransplantation model and mouse breast cancer xenografts were applied to validate the anti-metastatic activity of the screened compound. RESULTS: Bioactivity-guided fractionation identified baohuoside I (BHS) as the key bioactive compound of XIAOPI formula in inhibiting TAMs/CXCL1 promoter activity. Functional studies revealed that BHS could significantly inhibit the migration and invasion as well as the expression of metastasis-related proteins in both human and mouse breast cancer cells, along with decreasing the proportion of breast cancer stem cells (CSCs). Furthermore, BHS could suppress the M2 phenotype polarization of TAMs and therefore attenuate their CXCL1 expression and secretion. Notably, mechanistic investigations validated TAMs/CXCL1 as the crucial target of BHS in suppressing breast cancer metastasis as exogenous addition of CXCL1 significantly abrogated the anti-metastatic effect of BHS on breast cancer cells. Moreover, BHS was highly safe in vivo as it exhibited no observable embryotoxicity or teratogenic effect on zebrafish embryos. More importantly, BHS remarkably suppressed breast cancer metastasis and TAMs/CXCL1 activity in both zebrafish breast cancer xenotransplantation model and mouse breast cancer xenografts. CONCLUSION: This study not only provides novel insights into TAMs/CXCL1 as a reliable screening target for anti-metastatic drug discovery, but also suggests BHS as a promising candidate drug for metastatic breast cancer treatment.


Subject(s)
Breast Neoplasms/drug therapy , Breast Neoplasms/pathology , Chemokine CXCL1/metabolism , Flavonoids/pharmacology , Macrophages/drug effects , Animals , Breast Neoplasms/metabolism , Cell Line, Tumor , Chemokine CXCL1/antagonists & inhibitors , Chemokine CXCL1/genetics , Coculture Techniques , Down-Regulation/drug effects , Drug Screening Assays, Antitumor , Drugs, Chinese Herbal/chemistry , Drugs, Chinese Herbal/pharmacology , Embryo, Nonmammalian , Female , Humans , Macrophages/metabolism , Macrophages/pathology , Mice, Inbred BALB C , Neoplasm Metastasis , Neoplastic Stem Cells/drug effects , Xenograft Model Antitumor Assays , Zebrafish/embryology
7.
Life Sci ; 248: 117456, 2020 May 01.
Article in English | MEDLINE | ID: mdl-32097666

ABSTRACT

AIMS: In this study, we will investigate the therapeutic effects of berberine (BBR) in Helicobacter pylori (H. pylori) induced chronic atrophic gastritis (CAG). Furthermore, potential mechanisms of BBR in regulating IRF8-IFN-γ signaling axis will also be investigated. MATERIALS AND METHODS: H. pylori were utilized to establish CAG model of rats. Therapeutic effects of BBR on serum supernatant indices, and histopathology of stomach were analyzed in vivo. Moreover, GES-1 cells were infected by H. pylori, and intervened with BBR in vitro. Cell viability, morphology, proliferation, and quantitative analysis were detected by high-content screening (HCS) imaging assay. To further investigate the potential mechanisms of BBR, relative mRNA, immunohistochemistry and protein expression in IRF8-IFN-γ signaling axis were measured. KEY FINDINGS: Results showed serum supernatant indices including IL-17, CXCL1, and CXCL9 were downregulated by BBR intervention, while, G-17 increased significantly. Histological injuries of gastric mucosa induced by H. pylori also were alleviated. Moreover, cell viability and morphology changes of GES-1 cells were improved by BBR intervention. In addition, proinflammatory genes and IRF8-IFN-γ signaling axis related genes, including Ifit3, Upp1, USP18, Nlrc5, were suppressed by BBR administration in vitro and in vivo. The proteins expression related to IRF8-IFN-γ signaling axis, including Ifit3, IRF1 and Ifit1 were downregulated by BBR intervention.


Subject(s)
Anti-Inflammatory Agents/pharmacology , Berberine/pharmacology , Gastritis, Atrophic/drug therapy , Helicobacter Infections/drug therapy , Interferon Regulatory Factors/genetics , Interferon-gamma/genetics , Animals , Cell Line , Cell Proliferation/drug effects , Cell Survival/drug effects , Chemokine CXCL1/antagonists & inhibitors , Chemokine CXCL1/genetics , Chemokine CXCL1/immunology , Chemokine CXCL9/antagonists & inhibitors , Chemokine CXCL9/genetics , Chemokine CXCL9/immunology , Chronic Disease , Disease Models, Animal , Epithelial Cells/drug effects , Epithelial Cells/immunology , Epithelial Cells/microbiology , Gastritis, Atrophic/genetics , Gastritis, Atrophic/immunology , Gastritis, Atrophic/microbiology , Gene Expression Regulation , Helicobacter Infections/genetics , Helicobacter Infections/immunology , Helicobacter Infections/microbiology , Helicobacter pylori/drug effects , Helicobacter pylori/growth & development , Helicobacter pylori/pathogenicity , Humans , Interferon Regulatory Factors/antagonists & inhibitors , Interferon Regulatory Factors/immunology , Interferon-gamma/antagonists & inhibitors , Interferon-gamma/immunology , Interleukin-17/agonists , Interleukin-17/genetics , Interleukin-17/immunology , Male , NLR Proteins/antagonists & inhibitors , NLR Proteins/genetics , NLR Proteins/immunology , Rats , Rats, Sprague-Dawley , Signal Transduction , Uridine Phosphorylase/antagonists & inhibitors , Uridine Phosphorylase/genetics , Uridine Phosphorylase/immunology
8.
Am J Chin Med ; 47(7): 1611-1626, 2019.
Article in English | MEDLINE | ID: mdl-31645125

ABSTRACT

The medicinal mushroom Antrodia cinnamomea has been demonstrated to have anti-inflammatory properties. However, the bioactive compounds in A. cinnamomea need further investigation. The present study aimed to understand the mechanism of action of antcamphin M, an ergostanoid isolated from A. cinnamomea mycelium and to clarify its underlying mechanisms of action. RAW264.7 cells were pretreated with the indicated concentrations of antcamphin M, prior to stimulation with lipopolysaccharide (LPS). Cell viability, production of nitric oxide (NO), prostaglandin E2 (PGE2), cytokines, and chemokines, as well as the inflammation-related signaling pathways were investigated. The study revealed that antcamphin M significantly decreased the LPS-induced production of NO, PGE2, pro-inflammatory cytokines, and keratinocyte chemoattractant CXCL1 (KC), along with the levels of inducible NO synthase (iNOS) and cyclooxygenase-2 (COX-2) proteins without significant cytotoxicity, indicating it had a better anti-inflammatory activity than that of gisenoside Rb1 and Rg1. Additionally, antcamphin M significantly inhibited the activation of MAPKs (p38, ERK, and JNK), NFκB, and components of the NLRP3 inflammasome (NLRP3, ASC, and caspase-1) signaling pathways and also increased the levels of nuclear factor erythroid-2-related factor (Nrf2) and heme oxygenase-1 (HO-1). These findings suggest that antcamphin M possesses potent anti-inflammatory activities and could be a potential candidate for the development of anti-inflammatory drugs.


Subject(s)
Anti-Inflammatory Agents/pharmacology , Drugs, Chinese Herbal/pharmacology , Ergosterol/analogs & derivatives , Heme Oxygenase-1/immunology , Inflammasomes/immunology , NF-E2-Related Factor 2/immunology , NLR Family, Pyrin Domain-Containing 3 Protein/immunology , Toll-Like Receptor 4/immunology , Animals , Antrodia/chemistry , Chemokine CXCL1/genetics , Chemokine CXCL1/immunology , Dinoprostone/immunology , Ergosterol/pharmacology , Heme Oxygenase-1/genetics , Inflammasomes/genetics , Macrophages/drug effects , Macrophages/immunology , Mice , NF-E2-Related Factor 2/genetics , NLR Family, Pyrin Domain-Containing 3 Protein/genetics , Nitric Oxide/immunology , RAW 264.7 Cells , Signal Transduction/drug effects , Toll-Like Receptor 4/genetics
9.
Biomed Pharmacother ; 120: 109519, 2019 Dec.
Article in English | MEDLINE | ID: mdl-31629951

ABSTRACT

XIAOPI formula is a national approved drug prescribed to patients with high breast cancer risk. Previously we demonstrated that XIAOPI formula could inhibit breast cancer metastasis via suppressing CXCL1 expression, and postulated that "autophagy in cancer" might be one of its most core anti-cancer mechanisms. However, whether XIAOPI formula could be simultaneously applied with chemodrugs and their synergistic mechanisms are still remained unknown. In the present study, XIAOPI formula at non-cytotoxic doses could synergistically enhance the chemosensitivity of breast cancer cells MDA-MB-231 and MCF-7. We found that rapamycin-induced autophagy could reduce the chemosensitivity of breast cancer cells to XIAOPI formula, and the autophagy suppression and chemosensitizing activity of this formula was CXCL1-dependent. The evidence came from that XIAOPI formula was associated with a lower expression of CXCL1 combined with either rapamycin or taxol alone. Besides, the inhibitory effect of XIAOPI formula on the LC3-II and ABCG2 signals was weakened following CXCL1 over-expression, whereas P62 upregulation induced by XIAOPI formula was re-declined. A high throughput - qPCR (HT-qPCR) assay identified HMGB1 as the main autophagic target of XIAOPI formula in chemosensitizing breast cancer. and furhter validation suggested XIAOPI formula exerted chemosensitivity mainly via CXCL1/HMGB1 autophagic axis. Finally, we generated both mice and zebrafish xenotransplantation models bearing MDA-MB-231 breast cancer cells, and found that XIAOPI formula safely enhanced in vivo taxol chemosensitivity on breast cancer. Taken together, XIAOPI formula is a potential adjuvant drug via inhibiting CXCL1/HMGB1-mediated autophagy for breast cancer treatment with good safety.


Subject(s)
Breast Neoplasms/drug therapy , Chemokine CXCL1/metabolism , Drug Resistance, Neoplasm/drug effects , Drugs, Chinese Herbal/pharmacology , HMGB1 Protein/metabolism , Animals , Antineoplastic Agents/administration & dosage , Antineoplastic Agents/metabolism , Antineoplastic Agents/pharmacology , Autophagy , Cell Line , Cell Survival , Chemokine CXCL1/genetics , Drug Synergism , Epirubicin/metabolism , Female , Gene Expression Regulation/drug effects , HMGB1 Protein/genetics , Human Umbilical Vein Endothelial Cells , Humans , Mice , Mice, Nude , Neoplasms, Experimental/drug therapy , Oviposition/drug effects , Paclitaxel/administration & dosage , Paclitaxel/pharmacology , Zebrafish
10.
J Immunol Res ; 2018: 5038172, 2018.
Article in English | MEDLINE | ID: mdl-29854840

ABSTRACT

This work is aimed at investigating the effect of melittin on identified key genes in bladder cancer (BC) and further providing a theoretical basis for BC treatment. GSE35014 downloaded from the Gene Expression Omnibus (GEO) database was used to screen differentially expressed genes (DEGs) in BC cells and control. Results showed that a total of 389 upregulated and 169 downregulated genes were identified. Subsequently, GO analysis, KEGG pathway enrichment analysis, and PPI network analysis were employed to disclose the crucial genes and signaling pathways involved in BC. Fifteen module-related DEGs and their associated signaling pathways were obtained according to the PPI network and modular analyses. Based on the analysis of articles retrieved in the PubMed database, we found that melittin could induce apoptosis and constrain the progression of tumor cells as a result of regulating critical cancer-related signaling pathways, such as PI3K-Akt and TNF signaling pathways. Furthermore, PI3K-Akt and TNF signaling pathways were also found to be associated with module-related DEGs according to biological analyses. At last, qRT-PCR analysis demonstrated that melittin could constrain the expression of module-related DEGs (LPAR1, COL5A1, COL6A2, CXCL1, CXCL2, and CXCL3) associated with PI3K-Akt and TNF signaling pathways in BC cells. Functional assays revealed that melittin could constrain the proliferative and migrated abilities of BC cells. Conjointly, these findings provide a theoretical basis for these six genes as drug-sensitive markers of melittin in BC treatment.


Subject(s)
Medicine, Chinese Traditional , Melitten/therapeutic use , Urinary Bladder Neoplasms/genetics , Bee Venoms/metabolism , Chemokine CXCL1/genetics , Chemokine CXCL1/metabolism , Chemokine CXCL2/genetics , Chemokine CXCL2/metabolism , Chemokines, CXC/genetics , Chemokines, CXC/metabolism , Collagen Type V/genetics , Collagen Type V/metabolism , Collagen Type VI/genetics , Collagen Type VI/metabolism , Databases, Nucleic Acid , Datasets as Topic , Gene Expression Regulation, Neoplastic/drug effects , Gene Regulatory Networks/genetics , Humans , Melitten/metabolism , Phosphatidylinositol 3-Kinases/metabolism , Protein Interaction Maps , Proto-Oncogene Proteins c-akt/metabolism , Receptors, Lysophosphatidic Acid/genetics , Receptors, Lysophosphatidic Acid/metabolism , Signal Transduction , Tumor Necrosis Factors/metabolism , Urinary Bladder Neoplasms/drug therapy
11.
Mol Cancer Ther ; 17(7): 1515-1525, 2018 07.
Article in English | MEDLINE | ID: mdl-29643149

ABSTRACT

Adjuvant chemotherapy is used for human breast cancer patients, even after curative surgery of primary tumor, to prevent tumor recurrence primarily as a form of metastasis. However, anticancer drugs can accelerate metastasis in several mouse metastasis models. Hence, we examined the effects of postsurgical administration with 5-fluorouracil (5-FU), doxorubicin, and cyclophosphamide, on lung metastasis process, which developed after the resection of the primary tumor arising from the orthotopic injection of a mouse triple-negative breast cancer cell line, 4T1. Only 5-FU markedly increased the numbers and sizes of lung metastasis foci, with enhanced tumor cell proliferation and angiogenesis as evidenced by increases in Ki67-positive cell numbers and CD31-positive areas, respectively. 5-FU-mediated augmented lung metastasis was associated with increases in intrapulmonary neutrophil numbers and expression of neutrophilic chemokines, Cxcl1 and Cxcl2 in tumor cells, with few effects on intrapulmonary T-cell or macrophage numbers. 5-FU enhanced Cxcl1 and Cxcl2 expression in 4T1 cells in a NFκB-dependent manner. Moreover, the administration of a neutrophil-depleting antibody or a Cxcr2 antagonist, SB225002, significantly attenuated 5-FU-mediated enhanced lung metastasis with depressed neutrophil infiltration. Furthermore, infiltrating neutrophils and 4T1 cells abundantly expressed prokineticin-2 (Prok2) and its receptor, Prokr1, respectively. Finally, the administration of 5-FU after the resection of the primary tumor failed to augment lung metastasis in the mice receiving Prokr1-deleted 4T1 cells. Collectively, 5-FU can enhance lung metastasis by inducing tumor cells to produce Cxcl1 and Cxcl2, which induced the migration of neutrophils expressing Prok2 with a capacity to enhance 4T1 cell proliferation. Mol Cancer Ther; 17(7); 1515-25. ©2018 AACR.


Subject(s)
Breast Neoplasms/drug therapy , Gastrointestinal Hormones/genetics , Lung Neoplasms/drug therapy , Neovascularization, Pathologic/drug therapy , Neuropeptides/genetics , Receptors, G-Protein-Coupled/genetics , Animals , Breast Neoplasms/genetics , Breast Neoplasms/pathology , Cell Proliferation/drug effects , Chemokine CXCL1/genetics , Chemokine CXCL2/genetics , Cyclophosphamide/pharmacology , Doxorubicin/pharmacology , Female , Fluorouracil/pharmacology , Gene Expression Regulation, Neoplastic/drug effects , Humans , Lung Neoplasms/genetics , Lung Neoplasms/pathology , Lung Neoplasms/secondary , Macrophages/drug effects , Macrophages/pathology , Mammary Neoplasms, Animal/drug therapy , Mammary Neoplasms, Animal/genetics , Mammary Neoplasms, Animal/pathology , Mice , Neoplasm Metastasis , Neovascularization, Pathologic/genetics , Neovascularization, Pathologic/pathology , Neutrophils/drug effects , Neutrophils/pathology , T-Lymphocytes/drug effects
12.
Basic Clin Pharmacol Toxicol ; 119(6): 540-547, 2016 Dec.
Article in English | MEDLINE | ID: mdl-27194111

ABSTRACT

The compound 5-fluorouracil (5-FU) is used in cancer chemotherapy and is known to cause diarrhoea. We recently reported that chemokine (C-X-C motif) ligand 1 (CXCL1) and neutrophils in the colonic mucosa were markedly increased by the administration of 5-FU in mice. Curcumin has anti-inflammatory, antitumour and antioxidant properties. Therefore, we examined the effect of curcumin on 5-FU-induced diarrhoea development and CXCL1 and CXCL2 up-regulation in the colon. Mice were given 5-FU (50 mg/kg, i.p.) daily for 4 days. Curcumin (100 or 300 mg/kg, p.o.) was administered on the day before the first administration of 5-FU and administered 30 min. before the administration of 5-FU. Gene expression levels of CXCL1 and CXCL2 in the colon were examined by real-time RT-PCR. Curcumin reduced the 5-FU-induced diarrhoea development. Under this condition, the CXCL1 and CXCL2 gene up-regulated by 5-FU administration was inhibited by curcumin. The gene expression of CXCL1 and CXCL2 was also enhanced by 5-FU application in vitro. The 5-FU-induced up-regulated CXCL1 and CXCL2 gene expressions were inhibited by curcumin, Bay-117082 and bortezomib, nuclear factor kappa B (NF-κB) inhibitors, C646, a p300/cyclic adenosine monophosphate response element-binding protein-histone acetyltransferase (HAT) inhibitor. In conclusion, these findings suggested that curcumin prevented the development of diarrhoea by inhibiting NF-κB and HAT activation.


Subject(s)
Antimetabolites, Antineoplastic/adverse effects , Antioxidants/therapeutic use , Colon, Descending/drug effects , Curcumin/therapeutic use , Diarrhea/prevention & control , Dietary Supplements , Fluorouracil/adverse effects , Animals , Anti-Inflammatory Agents, Non-Steroidal/administration & dosage , Anti-Inflammatory Agents, Non-Steroidal/pharmacology , Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Antimetabolites, Antineoplastic/chemistry , Antimetabolites, Antineoplastic/pharmacology , Antioxidants/administration & dosage , Antioxidants/pharmacology , Chemokine CXCL1/agonists , Chemokine CXCL1/antagonists & inhibitors , Chemokine CXCL1/genetics , Chemokine CXCL1/metabolism , Chemokine CXCL2/agonists , Chemokine CXCL2/antagonists & inhibitors , Chemokine CXCL2/genetics , Chemokine CXCL2/metabolism , Colon, Descending/immunology , Colon, Descending/metabolism , Colon, Descending/physiopathology , Curcumin/administration & dosage , Curcumin/pharmacology , Diarrhea/chemically induced , Diarrhea/metabolism , Diarrhea/physiopathology , E1A-Associated p300 Protein/agonists , E1A-Associated p300 Protein/antagonists & inhibitors , E1A-Associated p300 Protein/metabolism , Enzyme Inhibitors/pharmacology , Fluorouracil/antagonists & inhibitors , Fluorouracil/pharmacology , Gene Expression Regulation/drug effects , Intestinal Mucosa/drug effects , Intestinal Mucosa/immunology , Intestinal Mucosa/metabolism , Intestinal Mucosa/physiopathology , Male , Mice, Inbred C57BL , NF-kappa B/agonists , NF-kappa B/antagonists & inhibitors , NF-kappa B/metabolism , Severity of Illness Index , Tissue Culture Techniques
13.
J Ethnopharmacol ; 173: 370-82, 2015 Sep 15.
Article in English | MEDLINE | ID: mdl-26239152

ABSTRACT

ETHNOPHARMACOLOGICAL RELEVANCE: Four traditional Chinese herbal remedies (CHR) including Buyang Huanwu decoction (BHD), Xuefu Zhuyu decoction (XZD), Tianma Gouteng decoction (TGD) and Shengyu decoction (SYD) are popular used in treating brain-related dysfunction clinically with different syndrome/pattern based on traditional Chinese medicine (TCM) principles, yet their neuroprotective mechanisms are still unclear. MATERIALS AND METHODS: Mice were subjected to an acute ischemic stroke to examine the efficacy and molecular mechanisms of action underlying these CHR. RESULTS: CHR treatment significantly enhanced the survival rate of stroke mice, with BHD being the most effective CHR. All CHR were superior to recombinant tissue-type plasminogen activator (rt-PA) treatment in successfully ameliorating brain function, infarction, and neurological deficits in stroke mice that also paralleled to improvements in blood-brain barrier damage, inflammation, apoptosis, and neurogenesis. Transcriptome analyses reveals that a total of 774 ischemia-induced probe sets were significantly modulated by four CHR, including 52 commonly upregulated genes and 54 commonly downregulated ones. Among them, activation of neurogenesis-associated signaling pathways and down-regulating inflammation and apoptosis pathways are key common mechanisms in ischemic stroke protection by all CHR. Besides, levels of plasma CX3CL1 and S100a9 in patients could be used as biomarkers for therapeutic evaluation before functional recovery could be observed. CONCLUSION: Our results suggest that using CHR, a combinatory cocktail therapy, is a better way than rt-PA for treating cerebral ischemic-associated diseases through modulating a common as well as a specific group of genes/pathways that may partially explain the syndrome differentiation and treatment principle in TCM.


Subject(s)
Drugs, Chinese Herbal/therapeutic use , Infarction, Middle Cerebral Artery/drug therapy , Neuroprotective Agents/therapeutic use , Animals , Calgranulin B/genetics , Chemokine CXCL1/genetics , Drug Therapy, Combination , Drugs, Chinese Herbal/pharmacology , Gene Expression Profiling , Infarction, Middle Cerebral Artery/genetics , Male , Medicine, Chinese Traditional , Mice, Inbred ICR , Neurogenesis/drug effects , Neuroprotective Agents/pharmacology , Phytotherapy
14.
Ann Allergy Asthma Immunol ; 114(1): 43-51.e1, 2015 Jan.
Article in English | MEDLINE | ID: mdl-25465920

ABSTRACT

BACKGROUND: Maternal asthma is a risk factor for asthma in offspring; however, transmission of the risk for allergic asthma without direct offspring sensitization has not been explored. OBJECTIVE: To determine whether offspring from mothers with ovalbumin (OVA)-sensitized asthma would develop airway disease at first-ever exposure to OVA and whether preconception maternal treatment with the Antiasthma Simplified Herbal Medicine Intervention (ASHMI) or dexamethasone (DEX) could modify this risk in offspring. METHODS: Female BALB/c mice (F0) with OVA-induced asthma were generated using established protocols. Mice with asthma were treated with ASHMI, DEX, or water for 6 to 7 weeks. Naive mice served as controls. Subsequently, mice were mated. Twelve-day-old F1 offspring received 3 consecutive intranasal low- or high-dose OVA exposures without sensitization. Forty-eight hours later, airway inflammation, mucus hypersecretion, serum antibodies, and cytokines were evaluated. RESULTS: Offspring from OVA-sensitized mothers, but not naive mothers, showed eosinophilic and neutrophilic airway inflammation, and mucus hyperplasia after OVA exposure and he presence of OVA-specific IgG1 and IgG2a. Offspring of ASHMI- and DEX-treated mothers showed decreased airway inflammation and mucus hypersecretion after low-dose OVA (P < .05-.001 for the 2 comparisons vs offspring of OVA/Sham mothers). Offspring of ASHMI-treated, but not DEX-treated, mothers were protected after the high-dose OVA challenge (P < .05-.01 vs offspring OVA/Sham). Maternal ASHMI therapy was associated with increased IgG2a (P < .01 vs offspring of OVA/Sham mothers) and decreased bronchoalveolar lavage fluid CXCL-1 and eotaxin-1 levels (P < .01 and P < .05, respectively, vs offspring of OVA/Sham mothers). CONCLUSION: Offspring of mothers with OVA-induced asthma developed airway inflammation and mucus to first-ever OVA exposure without prior sensitization. Maternal therapy with ASHMI was superior to DEX in decreasing offspring susceptibility to airway disease and could be a strategy to lower asthma prevalence.


Subject(s)
Asthma/therapy , Drugs, Chinese Herbal/administration & dosage , Immunity, Maternally-Acquired/drug effects , Lung/drug effects , Pneumonia/prevention & control , Adult Children , Animals , Antibodies/blood , Asthma/immunology , Chemokine CCL11/genetics , Chemokine CCL11/metabolism , Chemokine CXCL1/genetics , Chemokine CXCL1/metabolism , Cytokines/blood , Dexamethasone/administration & dosage , Disease Models, Animal , Female , Immunity, Innate/drug effects , Lung/immunology , Male , Maternal Exposure/adverse effects , Mice , Mice, Inbred BALB C , Pregnancy
15.
J Genet ; 93(3): 755-65, 2014 Dec.
Article in English | MEDLINE | ID: mdl-25572234

ABSTRACT

In pathogen resistant plants, solvent-exposed residues in the leucine-rich repeat (LRR) proteins are thought to mediate resistance by recognizing plant pathogen elicitors. In potato, the gene Gro1-4 confers resistance to Globodera rostochiensis. The investigation of variability in different copies of this gene represents a good model for the verification of positive selection mechanisms. Two datasets of Gro1 LRR sequences were constructed, one derived from the Gro1-4 gene, belonging to different cultivated and wild Solanum species, and the other belonging to paralogues of a resistant genotype. Analysis of nonsynonymous to synonymous substitution rates (K(a)/K(s)) highlighted 14 and six amino acids with K(a)/K(s) >1 in orthologue and paralogue datasets, respectively. Selection analysis revealed that the leucine-rich regions accumulate variability in a very specific way, and we found that some combinations of amino acids in these sites might be involved in pathogen recognition. The results confirm previous studies on positive selection in the LRR domain of R protein in Arabidopsis and other model plants and extend these to wild Solanum species. Moreover, positively selected sites in the Gro1 LRR domain show that coevolution mainly occurred in two regions on the internal surface of the three-dimensional horseshoe structure of the domain, albeit with different evolutionary forces between paralogues and orthologues.


Subject(s)
Chemokine CXCL1/genetics , Proteins/genetics , Selection, Genetic/genetics , Solanum/genetics , Amino Acid Substitution/genetics , Disease Resistance/genetics , Evolution, Molecular , Leucine-Rich Repeat Proteins , Mutation Rate , Plant Diseases/genetics
16.
RNA ; 18(12): 2236-50, 2012 Dec.
Article in English | MEDLINE | ID: mdl-23118416

ABSTRACT

Cordycepin (3' deoxyadenosine) has long been used in the study of in vitro assembled polyadenylation complexes, because it terminates the poly(A) tail and arrests the cleavage complex. It is derived from caterpillar fungi, which are highly prized in Chinese traditional medicine. Here we show that cordycepin specifically inhibits the induction of inflammatory mRNAs by cytokines in human airway smooth muscle cells without affecting the expression of control mRNAs. Cordycepin treatment results in shorter poly(A) tails, and a reduction in the efficiency of mRNA cleavage and transcription termination is observed, indicating that the effects of cordycepin on 3' processing in cells are similar to those described in in vitro reactions. For the CCL2 and CXCL1 mRNAs, the effects of cordycepin are post-transcriptional, with the mRNA disappearing during or immediately after nuclear export. In contrast, although the recruitment of RNA polymerase II to the IL8 promoter is also unaffected, the levels of nascent transcript are reduced, indicating a defect in transcription elongation. We show that a reporter construct with 3' sequences from a histone gene is unaffected by cordycepin, while CXCL1 sequences confer cordycepin sensitivity to the reporter, demonstrating that polyadenylation is indeed required for the effect of cordycepin on gene expression. In addition, treatment with another polyadenyation inhibitor and knockdown of poly(A) polymerase α also specifically reduced the induction of inflammatory mRNAs. These data demonstrate that there are differences in the 3' processing of inflammatory and housekeeping genes and identify polyadenylation as a novel target for anti-inflammatory drugs.


Subject(s)
Deoxyadenosines/pharmacology , Gene Expression/drug effects , Inflammation/genetics , Inflammation/prevention & control , Polyadenylation/drug effects , Animals , Anti-Inflammatory Agents, Non-Steroidal/pharmacology , Cell Line , Chemokine CCL2/genetics , Chemokine CXCL1/genetics , DNA-Directed RNA Polymerases/metabolism , HeLa Cells , Humans , Inflammation/metabolism , Inflammation Mediators/antagonists & inhibitors , Inflammation Mediators/metabolism , Interleukin-8/genetics , Mice , Myocytes, Smooth Muscle/drug effects , Myocytes, Smooth Muscle/metabolism , NF-kappa B/metabolism , NIH 3T3 Cells , Promoter Regions, Genetic , RNA Stability/drug effects , RNA, Messenger/genetics , RNA, Messenger/metabolism , Respiratory Muscles/drug effects , Respiratory Muscles/metabolism , Tumor Necrosis Factor-alpha/pharmacology
17.
Carcinogenesis ; 33(12): 2507-19, 2012 Dec.
Article in English | MEDLINE | ID: mdl-23042094

ABSTRACT

In America and Western Europe, prostate cancer is the second leading cause of death in men. Emerging evidence suggests that chronic inflammation is a major risk factor for the development and metastatic progression of prostate cancer. We previously reported that the chemopreventive polyphenol curcumin inhibits the expression of the proinflammatory cytokines CXCL1 and -2 leading to diminished formation of breast cancer metastases. In this study, we analyze the effects of curcumin on prostate carcinoma growth, apoptosis and metastasis. We show that curcumin inhibits translocation of NFκB to the nucleus through the inhibition of the IκB-kinase (IKKß, leading to stabilization of the inhibitor of NFκB, IκBα, in PC-3 prostate carcinoma cells. Inhibition of NFκB activity reduces expression of CXCL1 and -2 and abolishes the autocrine/paracrine loop that links the two chemokines to NFκB. The combination of curcumin with the synthetic IKKß inhibitor, SC-541, shows no additive or synergistic effects indicating that the two compounds share the target. Treatment of the cells with curcumin and siRNA-based knockdown of CXCL1 and -2 induce apoptosis, inhibit proliferation and downregulate several important metastasis-promoting factors like COX2, SPARC and EFEMP. In an orthotopic mouse model of hematogenous metastasis, treatment with curcumin inhibits statistically significantly formation of lung metastases. In conclusion, chronic inflammation can induce a metastasis prone phenotype in prostate cancer cells by maintaining a positive proinflammatory and prometastatic feedback loop between NFκB and CXCL1/-2. Curcumin disrupts this feedback loop by the inhibition of NFκB signaling leading to reduced metastasis formation in vivo.


Subject(s)
Antineoplastic Agents/therapeutic use , Chemokine CXCL1/antagonists & inhibitors , Chemokine CXCL2/antagonists & inhibitors , Curcumin/therapeutic use , Prostatic Neoplasms/drug therapy , Animals , Apoptosis , Cell Line, Tumor , Chemokine CXCL1/genetics , Chemokine CXCL2/genetics , Humans , Male , Mice , NF-kappa B/antagonists & inhibitors , NF-kappa B/physiology , Neoplasm Metastasis , Prostatic Neoplasms/pathology , Signal Transduction , Xenograft Model Antitumor Assays
18.
J Clin Invest ; 122(10): 3647-51, 2012 Oct.
Article in English | MEDLINE | ID: mdl-22996693

ABSTRACT

Although long considered a promising treatment option for type 1 diabetes, pancreatic islet cell transformation has been hindered by immune system rejection of engrafted tissue. The identification of pathways that regulate post-transplant detrimental inflammatory events would improve management and outcome of transplanted patients. Here, we found that CXCR1/2 chemokine receptors and their ligands are crucial negative determinants for islet survival after transplantation. Pancreatic islets released abundant CXCR1/2 ligands (CXCL1 and CXCL8). Accordingly, intrahepatic CXCL1 and circulating CXCL1 and CXCL8 were strongly induced shortly after islet infusion. Genetic and pharmacological blockade of the CXCL1-CXCR1/2 axis in mice improved intrahepatic islet engraftment and reduced intrahepatic recruitment of polymorphonuclear leukocytes and NKT cells after islet infusion. In humans, the CXCR1/2 allosteric inhibitor reparixin improved outcome in a phase 2 randomized, open-label pilot study with a single infusion of allogeneic islets. These findings indicate that the CXCR1/2-mediated pathway is a regulator of islet damage and should be a target for intervention to improve the efficacy of transplantation.


Subject(s)
Chemokine CXCL1/physiology , Diabetes Mellitus, Type 1/surgery , Interleukin-8/physiology , Islets of Langerhans Transplantation/immunology , Islets of Langerhans/metabolism , Receptors, Interleukin-8A/physiology , Receptors, Interleukin-8B/physiology , Sulfonamides/therapeutic use , Adult , Animals , Blood Glucose/analysis , Cell Survival/drug effects , Chemokine CXCL1/biosynthesis , Chemokine CXCL1/genetics , Diabetes Mellitus, Experimental/blood , Diabetes Mellitus, Experimental/genetics , Diabetes Mellitus, Experimental/surgery , Diabetes Mellitus, Type 1/immunology , Drug Evaluation, Preclinical , Female , Graft Rejection/prevention & control , Graft Survival/drug effects , Humans , Islets of Langerhans/immunology , Islets of Langerhans/pathology , Male , Mice , Mice, Inbred BALB C , Mice, Inbred C57BL , Middle Aged , Natural Killer T-Cells/immunology , Neutrophils/immunology , Pilot Projects , Receptors, Interleukin-8A/antagonists & inhibitors , Receptors, Interleukin-8B/antagonists & inhibitors , Receptors, Interleukin-8B/deficiency , Receptors, Interleukin-8B/genetics , Sulfonamides/pharmacology , Treatment Outcome
19.
J Immunol ; 188(7): 3458-68, 2012 Apr 01.
Article in English | MEDLINE | ID: mdl-22379035

ABSTRACT

In prior studies, we demonstrated that 1) CXCL1/KC is essential for NF-κB and MAPK activation and expression of CXCL2/MIP-2 and CXCL5/LPS-induced CXC chemokine in Klebsiella-infected lungs, and 2) CXCL1 derived from hematopoietic and resident cells contributes to host immunity against Klebsiella. However, the role of CXCL1 in mediating neutrophil leukotriene B(4) (LTB(4)), reactive oxygen species (ROS), and reactive nitrogen species (RNS) production is unclear, as is the contribution of these factors to host immunity. In this study, we investigated 1) the role of CXCL1 in LTB(4), NADPH oxidase, and inducible NO synthase (iNOS) expression in lungs and neutrophils, and 2) whether LTB(4) postinfection reverses innate immune defects in CXCL1(-/-) mice via regulation of NADPH oxidase and iNOS. Our results demonstrate reduced neutrophil influx, attenuated LTB(4) levels, and decreased ROS and iNOS production in the lungs of CXCL1(-/-) mice after Klebsiella pneumoniae infection. Using neutrophil depletion and repletion, we found that neutrophils are the predominant source of pulmonary LTB(4) after infection. To treat immune defects in CXCL1(-/-) mice, we intrapulmonarily administered LTB(4). Postinfection, LTB(4) treatment reversed immune defects in CXCL1(-/-) mice and improved survival, neutrophil recruitment, cytokine/chemokine expression, NF-κB/MAPK activation, and ROS/RNS production. LTB(4) also enhanced myeloperoxidase, H(2)O(2,) RNS production, and bacterial killing in K. pneumoniae-infected CXCL1(-/-) neutrophils. These novel results uncover important roles for CXCL1 in generating ROS and RNS in neutrophils and in regulating host immunity against K. pneumoniae infection. Our findings suggest that LTB(4) could be used to correct defects in neutrophil recruitment and function in individuals lacking or expressing malfunctional CXCL1.


Subject(s)
Chemokine CXCL1/deficiency , Chemotaxis, Leukocyte/drug effects , Klebsiella Infections/drug therapy , Klebsiella pneumoniae/immunology , Leukotriene B4/therapeutic use , Lung/immunology , Neutrophils/drug effects , Pneumonia, Bacterial/drug therapy , Animals , Chemokine CXCL1/genetics , Chemokine CXCL1/physiology , Drug Evaluation, Preclinical , Female , Klebsiella Infections/immunology , Leukotriene B4/administration & dosage , Leukotriene B4/biosynthesis , Leukotriene B4/pharmacology , Lung/microbiology , Lung/pathology , Male , Mice , Mice, Inbred C57BL , Mice, Knockout , NADPH Oxidases/biosynthesis , NADPH Oxidases/genetics , Neutrophils/enzymology , Neutrophils/physiology , Nitric Oxide Synthase Type II/biosynthesis , Nitric Oxide Synthase Type II/genetics , Peroxidase/metabolism , Pneumonia, Bacterial/immunology , Pneumonia, Bacterial/microbiology , Reactive Nitrogen Species/metabolism , Reactive Oxygen Species/metabolism
20.
Eur J Nutr ; 51(8): 927-37, 2012 Dec.
Article in English | MEDLINE | ID: mdl-22086299

ABSTRACT

PURPOSE: Extracts of the mushroom Agaricus blazei (A. blazei) have been described as possessing immunomodulatory and potentially cancer-protective activities. However, these effects of A. blazei as a functional food have not been fully investigated in vivo. METHODS: Using apolipoprotein E-deficient (ApoE(-/-)) mice, an experimental model of atherosclerosis, we evaluated the effects of 6 or 12 weeks of A. blazei supplementation on the activation of immune cells in the spleen and blood and on the development of atherosclerosis. RESULTS: Food intake, weight gain, blood lipid profile, and glycemia were similar between the groups. To evaluate leukocyte homing and activation, mice were injected with (99m)Tc-radiolabeled leukocytes, which showed enhanced leukocyte migration to the spleen and heart of A. blazei-supplemented animals. Analysis of the spleen showed higher levels of activation of neutrophils, NKT cells, and monocytes as well as increased production of TNF-α and IFN-γ. Circulating NKT cells and monocytes were also more activated in the supplemented group. Atherosclerotic lesion areas were larger in the aorta of supplemented mice and exhibited increased numbers of macrophages and neutrophils and a thinner fibrous cap. A. blazei-induced transcriptional upregulation of molecules linked to macrophage activation (CD36, TLR4), neutrophil chemotaxy (CXCL1), leukocyte adhesion (VCAM-1), and plaque vulnerability (MMP9) were seen after 12 weeks of supplementation. CONCLUSIONS: This is the first in vivo study showing that the immunostimulatory effect of A. blazei has proatherogenic repercussions. A. blazei enhances local and systemic inflammation, upregulating pro-inflammatory molecules, and enhancing leukocyte homing to atherosclerosis sites without affecting the lipoprotein profile.


Subject(s)
Agaricus/chemistry , Atherosclerosis/physiopathology , Dietary Supplements , Immunologic Factors/pharmacology , Inflammation/physiopathology , Animals , Aorta/drug effects , Aorta/physiopathology , Apolipoproteins E/deficiency , Atherosclerosis/immunology , CD36 Antigens/genetics , CD36 Antigens/metabolism , Cell Adhesion , Chemokine CXCL1/genetics , Chemokine CXCL1/metabolism , Disease Models, Animal , Fruiting Bodies, Fungal/chemistry , Inflammation/immunology , Interferon-gamma/immunology , Leukocytes/drug effects , Leukocytes/metabolism , Liver/drug effects , Liver/metabolism , Macrophage Activation/drug effects , Matrix Metalloproteinase 9/genetics , Matrix Metalloproteinase 9/metabolism , Mice , Mice, Knockout , Monocytes/immunology , Natural Killer T-Cells/drug effects , Natural Killer T-Cells/immunology , Neutrophils/immunology , Peroxidase/genetics , Peroxidase/metabolism , RNA, Messenger/genetics , RNA, Messenger/metabolism , Spleen/immunology , Spleen/metabolism , Spleen/pathology , Toll-Like Receptor 4/genetics , Toll-Like Receptor 4/metabolism , Tumor Necrosis Factor-alpha/immunology , Up-Regulation , Vascular Cell Adhesion Molecule-1/genetics , Vascular Cell Adhesion Molecule-1/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL